(VRCA) Verrica Pharmaceuticals Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VRCA) Verrica Pharmaceuticals Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Verrica Pharmaceuticals Inc. BCG Matrix is a company-specific strategic analysis that helps you see how its products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. The content on this page is a real preview of the actual report, so you can review the format and sample analysis before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.
Stars
YCANTH 0.7% FDA approved 2023
YCANTH, Verrica Pharmaceuticals Inc.’s cantharidin 0.7% topical solution, won FDA approval in 2023 for molluscum contagiosum in patients 2 years and older. It is the company’s main growth brand and its clearest high-share asset in the BCG Matrix. In Verrica’s portfolio, YCANTH fits the Stars bucket: high-growth market, strong brand position, and the key driver of future revenue.
Molluscum contagiosum 2 years and older
Molluscum contagiosum for patients aged 2 years and older is a strong Star for Verrica Pharmaceuticals Inc.: YCANTH is the first and only FDA-approved treatment in this market, so competition is thin. The addressable pool spans children and adults, and dermatology demand is broad because the infection is common and persistent. That supports a high-growth niche with room to scale.
First U.S. molluscum therapy
YCANTH became the first FDA-approved treatment for molluscum contagiosum in the United States in 2023, giving Verrica Pharmaceuticals Inc. a clear first-mover edge. That status helps drive brand recognition and physician prescribing momentum, which is why this fits a classic Star in the BCG Matrix. In its 2025 filings, Verrica still tied growth hopes to YCANTH adoption and label expansion.
Office applied dermatology workflow
YCANTH is a 0.7% cantharidin treatment applied in the physician office, so Verrica keeps direct prescriber control in a specialty channel. The label allows repeat dosing every 3 weeks for up to 4 treatments, which supports steady office use as adoption grows. This setup can help defend share because treatment stays tied to clinician workflow.
- 0.7% office-applied therapy
- Direct prescriber control
- Up to 4 treatments
- Supports share defense
Torii Japan VP-102 rights
Verrica licensed Japanese development and commercialization rights for VP-102 to Torii Pharmaceutical, so the cantharidin platform can grow in Japan without Verrica funding a full local launch. That partner-led model keeps the franchise expansion-focused and lowers direct operating risk. This matters because Verrica can pursue ex-U.S. upside while preserving cash.
- Japan rights sit with Torii Pharmaceutical.
- Cantharidin expands beyond the U.S.
- Partner funding reduces launch burden.
- Growth stays franchise-led, not capital-heavy.
YCANTH Powers Verrica’s Growth as a BCG Matrix Star
YCANTH is Verrica Pharmaceuticals Inc.’s Star in the BCG Matrix: it was the first FDA-approved treatment for molluscum contagiosum in 2023 and still anchors growth in 2025 filings. The 0.7% office-applied therapy has repeat dosing every 3 weeks for up to 4 treatments, supporting steady physician use and share defense. Japan rights sit with Torii Pharmaceutical, so ex-U.S. upside can grow without heavy launch spend.
What is included in the product
Detailed Word Document
Verrica’s BCG Matrix maps its portfolio to spot growth bets, cash generators, and divestiture risks.
Editable Excel File
Quick BCG Matrix for Verrica Pharmaceuticals Inc., revealing pain points and growth levers in one clean view.
Reference Sources
Provides a credible source trail for Verrica Pharmaceuticals Inc., helping users verify key claims fast and support better decisions.
Cash Cows
YCANTH repeat prescriptions
YCANTH can be prescribed in repeat cycles: one office application every 3 weeks, up to 4 treatments per course. Once dermatology offices adopt it, that schedule can make refill-like use steadier than a one-time launch spike.
That repeat pattern supports a more predictable revenue base, since follow-up visits can recur across a patient pool instead of resetting each quarter. For Verrica Pharmaceuticals Inc., YCANTH is the closest thing to a cash cow because it has the clearest path to recurring prescription volume.
Existing prescriber base
Verrica Pharmaceuticals Inc. has already built a dermatology prescriber base around YCANTH for molluscum contagiosum, and keeping those accounts is usually cheaper than building new ones. In 2024, Verrica reported net product revenue of $56.2 million, showing the franchise already has real refill and repeat-prescriber traction. Lower promotion intensity fits cash cow economics because the installed network can keep generating sales with less spend.
Commercial supply chain
YCANTH already needs commercial manufacturing, packaging, and distribution support, so the supply chain is a real operating asset for Verrica Pharmaceuticals Inc. The product is a 0.67% cantharidin topical solution, so each extra unit sold spreads fixed plant and logistics costs farther.
As volume rises, fixed operating leverage improves, which is why mature supply infrastructure can act like a cash cow. In FY2025, that leverage matters more because the same network can support higher YCANTH demand without a matching rise in overhead.
That makes the commercial supply chain a low-growth, cash-generating piece of the BCG Matrix.
Approved label ages 2 and older
Approved for ages 2 and older, Verrica Pharmaceuticals Inc.'s label covers a broad pediatric dermatology base, which supports repeat use without needing a new indication launch. That fits a Cash Cow profile: steady, lower-growth demand from an existing pool, not a new-market bet. In dermatology, a wide age label like 2+ can help keep prescribing consistent as the treated population stays large.
- Broad 2+ label
- Supports ongoing use
- No new indication needed
- Stable, lower-growth demand
Torii collaboration economics
Torii gives Verrica Pharmaceuticals Inc. a cash-cow style setup: Torii funds part of development, and Verrica can still earn milestone and royalty cash flow. That matters because YCANTH is already commercial, so partner economics can support growth without the same direct spend burden; the Torii deal includes up to $10 million in milestone payments plus tiered royalties.
- Partner funds more of the work.
- Milestones add non-dilutive cash.
- Royalties can scale with sales.
- Lower spend helps margins.
YCANTH Powers Verrica’s Steady Cash Cow Growth
YCANTH is Verrica Pharmaceuticals Inc.'s closest Cash Cow: repeat office dosing every 3 weeks, broad age 2+ use, and an installed dermatology base support steadier sales. Verrica reported $56.2 million in net product revenue in 2024, and the Torii deal can add up to $10 million in milestones plus tiered royalties.
| Cash Cow signal | Data |
|---|---|
| Net product revenue | $56.2M |
| Torii milestones | Up to $10M |
| YCANTH label | Age 2+ |
Preview the Actual Deliverable
Verrica Pharmaceuticals Inc. Reference Sources
You’re previewing the exact Verrica Pharmaceuticals Inc. BCG Matrix document you’ll receive after purchase. No sample pages or placeholder content—just the full, ready-to-use report. Download it immediately and use it for strategy, analysis, or presentation.
Dogs
VP-102 external genital warts Phase II
VP-102 for external genital warts reached Phase II, but it never became a marketed product. As of end-2025, Verrica Pharmaceuticals Inc. had no approved U.S. label for this program and no product sales tied to it, so its market share stayed at 0%. That low share and zero revenue fit the Dogs category in the BCG Matrix.
LTX-315 dermatology oncology license
LTX-315 is a licensed oncology candidate, not a commercial dermatology brand, so it sits in Verrica Pharmaceuticals Inc.'s Dogs bucket. As of end-2025, it had no marketed revenue stream for Verrica and no proven cash return. Until clinical progress or a partnering deal changes that, it remains a low-return asset.
Legacy unapproved cantharidin uses
Not every cantharidin program became an approved product, and those legacy uses can turn into stranded capital. Verrica Pharmaceuticals Inc. posted 2025 revenue of about $45 million, driven mainly by YCANTH, while it still carried R&D pressure from earlier pipeline work. If unapproved uses fail to advance, they fit the Dogs bucket: low growth, weak payoff, and sunk spending.
Pre-commercial clinical spend
Verrica Pharmaceuticals Inc.’s pre-commercial clinical spend fits a Dogs view: clinical-stage work burns cash before revenue starts, and long trials can tie up a small balance sheet. In BCG terms, that means low market share and low growth until a program is approved and scaled.
- Cash outflow comes before sales.
- Long trials pressure liquidity.
- Low share, low growth by design.
Non core pipeline complexity
Verrica Pharmaceuticals Inc.’s non-core pipeline adds small-program overhead, which can dilute focus and slow execution. When a program lacks a clear commercial path, it can keep cash and team time tied up without strong return, which is why it fits BCG "dog" traits. With R&D spend still constrained by a subscale pipeline, portfolio efficiency matters more than breadth.
- Small programs raise oversight load.
- Weak launch path traps capital.
- Focus shifts from winners to leftovers.
Verrica’s Dogs Burn Cash, Deliver No Sales
Verrica Pharmaceuticals Inc.’s Dogs are pre-commercial and legacy programs with no approved sales, so they bring cash burn but little payoff. In 2025, Verrica Pharmaceuticals Inc. had about $45 million revenue, mostly from YCANTH, while VP-102 and LTX-315 still had 0% market share and no marketed revenue.
| Asset | 2025 status |
|---|---|
| VP-102 | No approval, 0% share |
| LTX-315 | No sales, no cash return |
Question Marks
VP-103 plantar warts
VP-103 is Verrica Pharmaceuticals Inc.’s cantharidin-based candidate for plantar warts, a condition that affects about 7% to 10% of people and often comes back after treatment. That keeps the addressable market meaningful, but VP-103 is still unproven commercially and has no clear revenue base yet. With high upside and low share, it fits the BCG "question mark" bucket.
VP-102 common warts Phase II
VP-102 for common warts is still in Phase II, so it has clear upside but no approval yet. Common warts affect about 7% to 12% of people at some point, which makes the target market bigger than Verrica Pharmaceuticals Inc.’s current approved label. That mix of unmet need and regulatory risk is a classic Question Mark in the BCG Matrix.
Torii Japan common warts
Torii gives Verrica Pharmaceuticals Inc. rights to common warts in Japan, a 123 million-person market, so the geography can add upside. But Verrica has not built any disclosed commercial share there yet, so this stays a Question Mark in the BCG Matrix. Partnered growth means Torii drives uptake, but sales visibility is still limited.
Japan molluscum commercialization
Japan molluscum rights could open Verrica Pharmaceuticals Inc. to a large, new market, but this is still early-stage commercialization, not a proven revenue stream. Japan has about 123 million people, so the upside is real, yet uptake, pricing, and launch timing still need proof before this can move out of Question Mark status.
- New market upside, but unproven.
- Launch and uptake still uncertain.
- More data needed before scaling.
Future cantharidin label expansion
Verrica Pharmaceuticals Inc. cantharidin platform is still a question mark because YCANTH only has one approved use, molluscum contagiosum, while broader labels like common warts still depend on trial readouts and FDA review. The Company reported 2024 net product revenue of about $13 million and ended 2024 with roughly $40 million in cash, so any new indication could matter, but adoption is still unproven.
- One approved label today
- Expansion upside, but no certainty
- Cash supports the next readout
Verrica’s Question Marks: Big Upside, Still Unproven
Question Marks are Verrica Pharmaceuticals Inc. assets with clear upside but weak proof of scale. VP-103, VP-102, and Japan rights for common warts or molluscum could expand the market, but each still faces trial, launch, or uptake risk. With 2024 net product revenue near $13 million and cash around $40 million, the Company can fund the next step, but share is still unproven.
| Asset | Why it is a Question Mark |
|---|---|
| VP-103 | High upside, no sales base |
| VP-102 | Phase II only |
| Japan rights | Large market, no share yet |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.